[CASI] CASI Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.24 Change: 0.03 (2.48%)
Ext. hours: Change: 0 (0%)

chart CASI

Refresh chart

Strongest Trends Summary For CASI

CASI is in the long-term up 220% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company?s lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Fundamental Ratios
Shares Outstanding EPS-0.17 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-5.41
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-260.69% ROE1454.22% ROI
Current Ratio3.84 Quick Ratio Long Term Debt/Equity Debt Ratio-1.41
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities-1.21 M Gross Profit20 K
Net Profit-1.8 M Operating Profit-1.77 M Total Assets10.19 M Total Current Assets9.91 M
Total Current Liabilities2.58 M Total Debt1.41 M Total Liabilities12.01 M Total Revenue20 K
Technical Data
High 52 week8.23 Low 52 week2.77 Last close3.39 Last change0.3%
RSI24.77 Average true range0.23 Beta0.8 Volume47.53 K
Simple moving average 20 days-6.68% Simple moving average 50 days-13.64% Simple moving average 200 days-38.88%
Performance Data
Performance Week0.89% Performance Month-16.71% Performance Quart-2.59% Performance Half-53.75%
Performance Year-15.25% Performance Year-to-date-15.67% Volatility daily2.65% Volatility weekly5.93%
Volatility monthly12.15% Volatility yearly42.1% Relative Volume117.8% Average Volume352.03 K
New High New Low

News

2020-06-02 07:00:00 | CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference

2020-05-31 17:38:21 | Do Hedge Funds Love CASI Pharmaceuticals Inc CASI?

2020-05-25 06:14:35 | Wei-Wu He Is The Chairman & CEO of CASI Pharmaceuticals, Inc. NASDAQ:CASI And They Just Picked Up 32% More Shares

2020-05-14 06:47:13 | Earnings Update: CASI Pharmaceuticals, Inc. NASDAQ:CASI Just Reported And Analysts Are Boosting Their Estimates

2020-05-12 06:43:22 | Upgrade: Analysts Just Made A Notable Increase To Their CASI Pharmaceuticals, Inc. NASDAQ:CASI Forecasts

2020-05-11 07:00:00 | CASI Pharmaceuticals Announces First Quarter 2020 Financial Results

2020-05-08 09:05:00 | CASI: A Change in Strategy

2020-04-07 07:00:00 | CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference

2020-03-31 07:05:50 | CASI Pharmaceuticals, Inc. NASDAQ:CASI Analysts Just Slashed This Year's Estimates

2020-03-29 08:08:00 | Insider Buying: The CASI Pharmaceuticals, Inc. NASDAQ:CASI Chairman & CEO Just Bought US$1.1m Worth Of Shares

2020-03-16 07:00:00 | CASI Pharmaceuticals Announces Full Year 2019 Financial Results

2020-03-02 06:03:17 | Did Changing Sentiment Drive CASI Pharmaceuticals's NASDAQ:CASI Share Price Down By 47%?

2020-02-21 07:46:22 | The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

2020-02-07 10:49:03 | Ligand LGND Q4 Earnings & Revenues Top Estimates, Stock Up

2020-02-04 07:51:48 | The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

2020-01-26 08:33:24 | What You Must Know About CASI Pharmaceuticals, Inc.'s NASDAQ:CASI Beta Value

2019-12-20 05:27:00 | Have Insiders Been Buying CASI Pharmaceuticals, Inc. NASDAQ:CASI Shares?

2019-12-03 21:00:00 | CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 CD19 CAR-T Clinical Trial Applications

2019-11-14 05:17:47 | CASI Pharmaceuticals, Inc.'s NASDAQ:CASI Path To Profitability

2019-11-12 07:00:00 | CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results

2019-11-07 07:00:00 | CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable LAI Microsphere For Neuroendocrine Cancers And Acromegaly

2019-11-06 09:33:02 | Ligand's LGND Q3 Earnings Miss Estimates, EPS View Down

2019-09-19 07:00:00 | CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President

2019-09-16 06:00:00 | China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product

2019-09-03 07:00:00 | CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference

2019-08-20 19:15:15 | Casi Pharmaceuticals Inc CASI CEO Wei-wu He Bought $64,000 of Shares

2019-08-19 12:22:11 | What Kind Of Shareholders Own CASI Pharmaceuticals, Inc. NASDAQ:CASI?

2019-08-16 10:20:00 | CASI: CASI launches Evomela - first commercial product

2019-08-15 19:15:09 | Casi Pharmaceuticals Inc CASI CEO Wei-wu He Bought $507,200 of Shares

2019-08-12 15:03:45 | Rockville biopharma to sell first product on market in 28 years — but not in the U.S.

2019-08-12 07:00:00 | CASI Pharmaceuticals Announces Launch of EVOMELA® melphalan for injection in China

2019-08-09 07:00:00 | CASI Pharmaceuticals Announces Second Quarter and First Half 2019 Financial and Business Results

2019-07-31 10:44:02 | Ligand LGND Stock Down Despite Q2 Earnings & Sales Beat

2019-06-17 07:00:00 | CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy

2019-06-03 07:00:00 | CASI Pharmaceuticals To Present At The 2019 BIO International Convention

2019-05-20 09:45:00 | CASI: Making headway towards commercialization

2019-05-15 07:00:00 | CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results

2019-05-13 10:00:00 | CASI: Initiating coverage – Leveraging pharmaceutical opportunities in China and beyond

2019-05-03 08:42:12 | Ligand LGND Q1 Earnings & Sales Fall Y/Y, Stock Down

2019-04-18 16:15:00 | INVESTOR ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers

2019-04-17 07:00:00 | CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics

2019-04-02 07:00:00 | CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer

2019-03-29 07:00:00 | CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results

2019-03-13 07:00:00 | CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection EVOMELA® In China

2019-03-07 07:00:00 | CASI Pharmaceuticals Announces China National Medical Products Administration NMPA Approval Of CTA To Conduct Registration Trial For MARQIBO®

2019-02-26 08:14:52 | When Will CASI Pharmaceuticals, Inc. NASDAQ:CASI Turn A Profit?

2019-02-20 08:15:00 | Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett — Future Expectations, Projections Moving into 2019

2019-02-19 07:00:00 | CASI Pharmaceuticals Announces China National Medical Products Administration NMPA Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®

2019-02-06 07:00:00 | CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference

2018-12-28 11:45:00 | These 4 Healthcare Stocks Are Heating Up